Skip to Content
MilliporeSigma
All Photos(1)

Documents

E-067

Supelco

Ethosuximide solution

1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C7H11NO2
CAS Number:
77-67-8
Molecular Weight:
141.17
EC Number:
200-659-6
UNSPSC Code:
41116107

grade

certified reference material

feature

Snap-N-Spike®/Snap-N-Shoot®

packaging

ampule of 1 mL

manufacturer/tradename

Cerilliant®

concentration

1.0 mg/mL in methanol

format

single component solution

storage temp.

−20°C

SMILES string

CCC1(C)CC(=O)NC1=O

InChI

1S/C7H11NO2/c1-3-7(2)4-5(9)8-6(7)10/h3-4H2,1-2H3,(H,8,9,10)

InChI key

HAPOVYFOVVWLRS-UHFFFAOYSA-N

Gene Information

human ... CACNA1G(8913) , CACNA1H(8912) , CACNA1I(8911)

General description

Ethosuximide is an anticonvulsant specifically used to treat absence seizures. This Snap-N-Spike® Reference Solution is suitable for LC/MS or GC/MS applications in clinical toxicology, forensic analysis, urine drug testing, or pharmaceutical research.

Legal Information

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

related product

Product No.
Description
Pricing

B-006

Butalbital solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

S-002

Secobarbital solution, 1 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

P-008

Phenobarbital solution, 1 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

A-020

Amobarbital solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

B-024

Butabarbital solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

B-041

Barbiturate Mix-5 solution, 250 μg/mL each component in methanol, ampule of 1.0 mL, certified reference material, Cerilliant®

H-013

Hexobarbital solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

P-010

Pentobarbital solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

P-075

Primidone solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

signalword

Danger

Hazard Classifications

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

target_organs

Eyes

Storage Class

3 - Flammable liquids

wgk_germany

WGK 1

flash_point_f

49.5 °F - closed cup

flash_point_c

9.7 °C - closed cup

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Kinga K Borowicz et al.
Annals of agricultural and environmental medicine : AAEM, 19(3), 487-490 (2012-10-02)
Depression is becoming a growing problem in rural areas. This psychiatric disorder often accompanies epilepsy. The aim of this study was to assess the influence of fluoxetine (FXT), a commonly used antidepressant, on the protective action of two conventional antiepileptic
Stuart D Greenhill et al.
Neuropharmacology, 62(2), 807-814 (2011-09-29)
Ethosuximide is the drug of choice for treating generalized absence seizures, but its mechanism of action is still a matter of debate. It has long been thought to act by disrupting a thalamic focus via blockade of T-type channels and
Chinekwu Anyanwu et al.
Journal of child neurology, 28(1), 111-114 (2012-04-03)
Coexistence of 2 idiopathic epilepsy syndromes (ie, childhood absence and Rolandic epilepsy), as evidenced by electroencephalographic (EEG) findings with or without clinical features of the 2 conditions, is uncommon and remains controversial. Few case reports support this coexistence either as
Pue Farooque et al.
Epileptic disorders : international epilepsy journal with videotape, 13(4), 411-416 (2012-01-20)
Childhood absence epilepsy (CAE) typically starts between four and seven years of age. Onset before three years is rare and has not been previously reported from North America. We retrospectively reviewed the electroencephalography laboratory database and paediatric neurology clinic records
Tracy A Glauser et al.
Epilepsia, 54(1), 141-155 (2012-11-22)
Determine the optimal initial monotherapy for children with newly diagnosed childhood absence epilepsy (CAE) based on 12 months of double-blind therapy. A double-blind, randomized controlled clinical trial compared the efficacy, tolerability, and neuropsychological effects of ethosuximide, valproic acid, and lamotrigine
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service